| Bioactivity | Adebrelimab (SHR-1316) is a humanized IgG4 monoclonal PD-L1 (PD-1/PD-L1) antibody. Adebrelimab has promising antitumor activity in solid tumors including extensive-stage small-cell lung cancer (SCLC)[1][2]. |
| Invitro | Adebrelimab (SHR-1316; 0.06- 1mg/mL; 48 hours) 抑制 SK-BR-3 和 AU565 细胞的增殖、迁移、侵袭[1]。Adebrelimab（SHR-1316；0.1-1mg/mL；48 小时）下调 PD-L1、p-PI3K、p-AKT 的表达并上调 FOXO1 的表达[1]。SK-BR-3 and AU565 cells 0.1 mg/mL, 1 mg/mL48 hoursPromoted cell apoptosis.SK-BR-3 and AU565 cells 0.1 mg/mL, 1 mg/mL24 hoursDecreased the migration rate of SK-BR -3 and AU565 cells.SK-BR-3 and AU565 cells 0.1 mg/mL, 1 mg/mL48 hoursDownregulated the expression of PD-L1, p-PI3K, p-AKT and upregulated the expression FOXO1. Cell Viability Assay[1] Cell Line: |
| Name | Adebrelimab |
| CAS | 2247114-85-6 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |